| abstract |
Provided is a medicament for safely treating a patient in need of treatment with pemafibrate or a salt thereof or a solvate thereof (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, comprising pemafibrate or a salt thereof or a solvate thereof as an active ingredient, wherein the treatment comprises an OATP1B inhibitor In order to suppress an increase in the plasma concentration of pemafibrate during the combined use, a pharmaceutical comprising a step of avoiding or stopping the combined use or a step of reducing the dose of pemafibrate or a salt thereof or a solvate thereof. [Selection figure] None |